Edesa Biotech shares plummet following announcement of $25 million public offering.

EDSA · Edesa Biotech, Inc.

The AI's read

Edesa priced a $25M equity offering and shares plunged roughly 15% on dilution concerns. The drop came immediately, driven by the size and terms of the raise. The market has already moved hard, and the stock is deeply oversold with RSI at 9.7. That reduces short-term upside unless a near-term catalyst appears. The offering extends runway but increases share count and adds short-dated warrants that compress timing around clinical data. We lean neutral because the immediate damage looks priced in and the risk/reward is now binary around upcoming trial results.